

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**ORDER GRANTING THE FINAL APPLICATION OF REED SMITH LLP AS AN
ORDINARY COURSE PROFESSIONAL FOR COMPENSATION FOR SERVICES
RENDERED IN EXCESS OF THE TIER 1 OCP CAP FROM SEPTEMBER 1, 2021
THROUGH FEBRUARY 28, 2022**

Upon the application, dated April 18, 2022 (the “Application”) of Reed Smith LLP (“Reed Smith”) pursuant to sections 327 and 331 of title 11 of the United States Code (the “Bankruptcy Code”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), Rule 2016-1 of the Local Rules of Bankruptcy Procedure, incorporating the *Amended Guidelines for Fees and Disbursements for Professionals in the Southern District of New York Bankruptcy Cases* promulgated by the Board of Judges for the United States Bankruptcy Court for the Southern District of New York [General Order M-447], and the *Order Authorizing Debtors to Employ Professionals Used in the Ordinary Course of Business Nunc Pro Tunc to the Petition Date* [ECF No. 548] (the “OCP Order”), seeking allowance of compensation for professional services on behalf of the Debtors estates in excess of the Tier 1 OCP Cap² in the amount of \$285,393.00 from

¹ The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

² Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the OCP Order or the Application, as appropriate.

September 1, 2021 through February 28, 2022 (the “Fee Period”); and an independent fee examiner (the “Fee Examiner”) having been appointed in these cases in accordance with the *Order Authorizing Appointment of Independent Fee Examiner Pursuant to 11 U.S.C. § 105(a) and Modifying Interim Compensation Procedures for Certain Professionals Employed Pursuant to 11 U.S.C. § 327* [ECF No. 1023] (the “Fee Examiner Order”); and the Fee Examiner having reviewed the Application in accordance with the Fee Examiner Order; and the Fee Examiner and Reed Smith having agreed to the recommended fee reductions set forth on Schedule A hereto; and the Fee Examiner having no objection to payment of Reed Smith’s fees in the amount set forth on Schedule A hereto under the column heading “Amount of Fees in Excess of Tier 1 OCP Cap Allowed”; and due and sufficient notice having been provided pursuant to Bankruptcy Rules 2002(a)(6) and (c)(2) and the OCP Order, and it appearing that no other or further notice need be provided; and a hearing having been held on May 18, 2022 to consider the Application (the “Hearing”); and the Court having jurisdiction over this matter pursuant to 28 U.S.C. §§ 157(a)-(b) and 1334(b) and the Amended Standing Order of Reference M-431, dated January 31, 2012 (Preska, C.J.); and this matter being a core proceeding under 28 U.S.C. § 157(b)(2); and venue being proper before the Court pursuant to 28 U.S.C. §§ 1408 and 1409; and upon the record of all the Hearing; and there being no objections to the relief granted herein; and it appearing that the amount set forth on Schedules A and B hereto for which compensation is allowed hereby was actual, reasonable, and necessary; and good and sufficient cause appearing therefor,

IT IS HEREBY ORDERED THAT:

1. The Application is granted as set forth herein.

2. Reed Smith is awarded compensation for professional services rendered during the Fee Period in excess of the Tier 1 OCP Cap in the amount set forth on Schedules A and B hereto under the column heading “Amount of Fees in Excess of Tier 1 OCP Cap Allowed.”

3. The Debtors are authorized and directed to pay Reed Smith promptly the amounts of fees approved by this Order, to the extent such amounts have not previously been paid.

4. This Court shall retain jurisdiction to hear and determine all matters arising from or related to this Order.

Dated: May 19, 2022
White Plains, New York

/s/Robert D. Drain

HONORABLE ROBERT D. DRAIN
UNITED STATES BANKRUPTCY JUDGE

Case No.: **19-23649 (RDD)**

Case Name: **In re Purdue Pharma L.P., et al.**

CURRENT INTERIM FEE PERIOD

September 1, 2022 through February 28, 2022

Schedule A

(1) Applicant	(2) Date/Document Number of Application	(3) Amount of Fees in Excess of Tier 1 OCP Cap Requested	(4) Amount of Fees in Excess of Tier 1 OCP Cap Allowed*	(5) Fees to be Paid for Current Fee Period	(6) Fees to be Paid for Prior Fee Period(s) (if any) (i.e., Holdback Release)	(7) Total Fees to be Paid	(8) Expenses Requested	(9) Expenses to be Paid for Current Fee Period
Reed Smith LLP	April 18, 2022, ECF No. 4671	\$285,393.00	\$281,553.50	\$281,553.50	\$0	\$281,553.50	NA	NA

*Minus Agreed Recommended Reduction of Fees \$3,839.50

Case No.: **19-23649 (RDD)**

Case Name: **In re Purdue Pharma L.P., et al.**

FINAL FEE APPLICATION TOTALS

September 1, 2022 through February 28, 2022

Schedule B

(1) Applicant	(2) Total Fees Requested	(3) Total Fees Paid	(4) Total Expenses Requested	(5) Total Expenses Paid
Reed Smith LLP	\$285,393.00	\$281,553.50	NA	NA

DATE ON WHICH ORDER WAS SIGNED: May 18, 2022

INITIALS: RDD USBJ